Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 927

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 3
Chunk 927
---
(485.65)
  
    Change in Fair Value of Promissory Note 
     -  
     2,121.39 
  
    Other Income (Expense), net 
     16.70  
     (32.78)
  
    Total Interest and Other Income (Expense), net 
     289.60  
     528.85 
  
    Loss from Operations before Provision for Income Taxes 
     (1,309.37) 
     (1,503.93)
  
    Provision for Income Taxes (Note 9) 
     0.04  
     0.10 
  
    Net Loss including Noncontrolling Interest 
     (1,309.41) 
     (1,504.02)
  
    Net Loss – Noncontrolling Interest 
     (1.41) 
     (18.97)
  
    Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc. 
     (1,308.01)% 
     (1,485.06)%

4. Comparison of the Years Ended December
31, 2024, and 2023

Product Revenues - net of Discounts and Rebates, Cost of Revenues,
Gross Profit (Loss), and Gross Margin

    For the Year Ended
    December 31,  

    Consolidated Statements of Operations Data: 
    2024  
    2023  
    $ Change  
    % Change 
  
    Product Revenues – net of Discounts and Rebates 
    $607,574  
    $253,573  
    $354,001  
     139.61%
  
    Cost of Revenues 
     384,765  
     474,550  
     (89,785) 
     (18.92)
  
    Gross Profit (Loss) 
    $222,809  
    $(220,977) 
    $443,786  
     (200.83)%
  
    Gross Margin % 
     36.67% 
     (87.15)% 

Product Revenues - net of Discounts and Rebates

Our product revenues - net of discounts and rebates
were $607,574 for the year ended December 31, 2024, as compared to $253,573 for the year ended December 31, 2023. For the year ended
December